SEARCH:   Advanced

Blood, 15 November 2008, Vol. 112, No. 10, pp. 4213-4219. Prepublished online as a Blood First Edition Paper on August 15, 2008; DOI 10.1182/blood-2008-05-157255. This Article Full Text Full Text (PDF) Supplemental Methods All Versions of this Article: blood-2008-05-157255v1 112/10/4213    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Pallasch, C. P. Articles by Wendtner, C.-M. Search for Related Content PubMed PubMed Citation Articles by Pallasch, C. P. Articles by Wendtner, C.-M. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease Christian Philipp Pallasch1,*, Alexandra Schulz1,*, Nadine Kutsch1, Janine Schwamb1, Susanne Hagist1, Hamid Kashkar2, Alfred Ultsch3, Claudia Wickenhauser4,5, Michael Hallek1, and Clemens-Martin Wendtner1 1 Laboratory of Cellular Immunotherapy, Clinic I of Internal Medicine, and 2 Institute for Medical Microbiology and Immunology, University of Cologne, Cologne; 3 Databionics Research Group, Department of Mathematics & Computer Science, Philipps-University Marburg, Marburg; 4 Department of Pathology, University of Cologne, Cologne; and 5 Institute for Pathology, University of Leipzig, Leipzig, Germany Resistance toward apoptotic stimuli mediated by overexpression of antiapoptotic factors or extracellular survival signals is considered to be responsible for accumulation of malignant B cells in chronic lymphocytic leukemia (CLL). TOSO was identified as overexpressed candidate gene in CLL, applying unit-transformation assays of publicly available microarray datasets. Based on CLL samples from 106 patients, TOSO was identified to exhibit elevated relative expression (RE) of 6.8 compared with healthy donor B cells using quantitative real-time polymerase chain reaction (PCR; P = .004). High levels of TOSO expression in CLL correlated with high leukocyte count, advanced Binet stage, previous need for chemotherapy, and unmutated IgVH status. CD38+ CLL subsets harboring proliferative activity showed enhanced TOSO expression. We evaluated functional mechanisms of aberrant TOSO expression and identified TOSO expression significantly induced by B-cell receptor (BCR) stimulation compared with control cells (RE; 8.25 vs 4.86; P = .01). In contrast, CD40L signaling significantly reduced TOSO expression (RE, 2.60; P = .01). In summary, we show that the antiapoptotic factor TOSO is associated with progressive disease and enhanced in the proliferative CD38+ CLL subset. Both association with unmutated IgVH and the specific induction of TOSO via the BCR suggest autoreactive BCR signaling as a key mediator of apoptosis resistance in CLL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Kubagawa, S. Oka, Y. Kubagawa, I. Torii, E. Takayama, D.-W. Kang, G. L. Gartland, L. F. Bertoli, H. Mori, H. Takatsu, et al. Identity of the elusive IgM Fc receptor (Fc{micro}R) in humans J. Exp. Med., November 23, 2009; 206(12): 2779 - 2793. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020